Compounds having s1p5 receptor agonistic activity
Provided is a compound in which the balance of the agonist activity against the S1P5receptor relative to the S1P1receptor has been improved in order to develop a pharmaceutical useful for the treatment of S1P5-mediated diseases such as schizophrenia and Binswanger's disease and other neurodegen...
Gespeichert in:
Hauptverfasser: | , , , , , |
---|---|
Format: | Patent |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Provided is a compound in which the balance of the agonist activity against the S1P5receptor relative to the S1P1receptor has been improved in order to develop a pharmaceutical useful for the treatment of S1P5-mediated diseases such as schizophrenia and Binswanger's disease and other neurodegenerative diseases. This compound represented by general formula (V) (in the formula, all symbols are as defined in the specification) has an improved balance of the agonist activity against the S1P5receptor relative to the S1P1receptor, and can thus serve as a therapeutic for S1P5-mediated diseases such as schizophrenia and Binswanger's disease and other neurodegenerative diseases. |
---|